文献速递血液净化与透析

辅酶Q10对血液透析患者氧化应激生物标志物及心功能的影响:CoQ10生物标志物试验

Effect of Coenzyme Q10 on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ10 Biomarker Trial.
PubMed 文献 · Am J Kidney Dis · 2016-12-04

这项安慰剂对照、3组、双盲随机临床试验纳入65例每周三次维持性血液透析患者,随机接受每日辅酶Q10 600mg、1200mg或安慰剂4个月。结果显示每日1200mg(而非600mg)辅酶Q10显著降低4个月时血浆F2-异前列腺素浓度,但对异呋喃、心脏生物标志物或透析前血压无显著影响。

要点

  • 每日1200mg辅酶Q10显著降低血液透析患者4个月时血浆F2-异前列腺素浓度。
  • 每日600mg辅酶Q10对血浆F2-异前列腺素浓度无显著影响。
  • 辅酶Q10对异呋喃、心脏生物标志物及透析前血压均无显著影响。

核心结论

  • 在维持性血液透析患者中,每日补充1200mg辅酶Q10是安全的,并可降低血浆F2-异前列腺素浓度,后者是氧化应激的标志物。
  • 未来研究需要确定补充辅酶Q10是否能改善维持性血液透析患者的临床结局。

研究设计与样本

  • 安慰剂对照、3组、双盲、随机临床试验。
  • 65例每周三次维持性血液透析患者被随机按1:1:1比例分配接受每日一次辅酶Q10 600mg、1200mg或匹配安慰剂,为期4个月。

主要发现

  • 80例随机分配患者中,15例因未完成至少1次基线后研究访视被排除,65例纳入主要意向性治疗分析。
  • 未发生治疗相关的主要不良事件。
  • 每日1200mg辅酶Q10在4个月时较安慰剂显著降低血浆F2-异前列腺素浓度,校正平均变化为-10.7 pg/mL(95%CI,-7.1至-14.3;P<0.001)。
  • 每日600mg辅酶Q10在4个月时较安慰剂对血浆F2-异前列腺素浓度的校正平均变化为-8.3 pg/mL(95%CI,-5.5至-11.0;P=0.1),无显著影响。
  • 辅酶Q10治疗对血浆异呋喃水平、心脏生物标志物或透析前血压均无显著影响。

局限性

  • 研究未足以检测小的治疗效果。
  • 随机分组间基线特征存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oxidative stress is highly prevalent in patients with end-stage renal disease and is linked to excess cardiovascular risk. Identifying therapies that reduce oxidative stress has the potential to improve cardiovascular outcomes in patients undergoing maintenance dialysis. STUDY DESIGN: Placebo-controlled, 3-arm, double-blind, randomized, clinical trial. SETTING & PARTICIPANTS: 65 patients undergoing thrice-weekly maintenance hemodialysis. INTERVENTION: Patients were randomly assigned in a 1:1:1 ratio to receive once-daily coenzyme Q10 (CoQ10; 600 or 1,200mg) or matching placebo for 4 months. OUTCOMES: The primary outcome was plasma oxidative stress, defined as plasma concentration of F2-isoprotanes. Secondary outcomes included levels of plasma isofurans, levels of cardiac biomarkers, predialysis blood pressure, and safety/tolerability. MEASUREMENTS: F2-isoprostanes and isofurans were measured as plasma markers of oxidative stress, and N-terminal pro-brain natriuretic peptide and troponin T were measured as cardiac biomarkers at baseline and 1, 2, and 4 months. RESULTS: Of 80 randomly assigned patients, 15 were excluded due to not completing at least 1 postbaseline study visit and 65 were included in the primary intention-to-treat analysis. No treatment-related major adverse events occurred. Daily treatment with 1,200mg, but not 600mg, of CoQ10 significantly reduced plasma F2-isoprostanes concentrations at 4 months compared to placebo (adjusted mean changes of -10.7 [95% CI, -7.1 to -14.3] pg/mL [P<0.001] and -8.3 [95% CI, -5.5 to -11.0] pg/mL [P=0.1], respectively). There were no significant effects of CoQ10 treatment on levels of plasma isofurans, cardiac biomarkers, or predialysis blood pressures. LIMITATIONS: Study not powered to detect small treatment effects; difference in baseline characteristics among randomized groups. CONCLUSIONS: In patients undergoing maintenance hemodialysis, daily supplementation with 1,200mg of CoQ10 is safe and results in a reduction in plasma concentrations of F2-isoprostanes, a marker of oxidative stress. Future studies are needed to determine whether CoQ10 supplementation improves clinical outcomes for patients undergoing maintenance hemodialysis.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Rivara MB, Yeung CK, Robinson-Cohen C, et al. Effect of Coenzyme Q10 on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ10 Biomarker Trial. Am J Kidney Dis. 2016. PMID: 27927588. doi:10.1053/j.ajkd.2016.08.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。